+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls



In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls



Clinical Rheumatology 36(10): 2377-2381



Psoriatic Arthritis (PsA) is characterized by bone erosive damage often associated with exuberant bone formation especially in enthesial sites. Dkk-1 and sclerostin are the main inhibitors of the WNT/β-catenin signaling pathway and play a key role in the regulation of both bone formation and resorption. We performed this study in order to compare the serum levels of the WNT-pathway regulators along with bone turnover markers (BTM) and parathyroid hormone (PTH) between three different groups: one group of female patients affected by PsA, one group of female patients affected by rheumatoid arthritis (RA), and healthy female controls (HC). This is a cross-sectional study including 33 patients with PsA classified with the CASPAR criteria, 35 HC, and 28 patients with RA classified with the ACR/EULAR 2010 criteria. Intact N-propeptide of type I collagen (PINP), C-terminal telopeptide of type I collagen (CTX-I), Dickkopf-related-protein 1 (Dkk-1), sclerostin, PTH, and 25OH-vitamin D serum levels were dosed. The PsA group showed significantly lower Dkk-1 levels when compared to the HC and RA groups. Dkk-1 in the RA group was significantly higher than HC. A similar trend was documented for PTH. In the PsA group, CTX-I was found to be lower than in both the RA and HC groups. This study demonstrated for the first time that Dkk-1 levels in PsA are lower than HC, in contrast with RA, in which they are increased. These results might contribute to explain the different bone involvement of the two different diseases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059865579

Download citation: RISBibTeXText

PMID: 28634697

DOI: 10.1007/s10067-017-3734-2


Related references

HLA-DRB1*04 alleles in psoriatic arthritis: Comparison with rheumatoid arthritis and healthy controls. Human Immunology 62(11): 1239-1244, 2001

AB0574Prevalence of hla-drb1 in psoriatic arthritis, psoriasis and rheumatoid arthritis: comparison with healthy controls. Annals of the Rheumatic Diseases 72(Suppl 3): A965.1-A965, 2013

Frequency of Arthritis-Like MRI Findings in the Forefeet of Healthy Volunteers Versus Patients With Symptomatic Rheumatoid Arthritis or Psoriatic Arthritis. Ajr. American Journal of Roentgenology 208(2): W45-W53, 2017

SAT0515Seropositive Rheumatoid Arthritis has a Distinctive Bone Phenotype at the Ultra-Distal Radius Compared to Seronegative Rheumatoid Arthritis and Psoriatic Arthritis. Annals of the Rheumatic Diseases 72(Suppl 3): A756.1-A756, 2013

Lower Healthy Eating Index-2005 dietary quality scores in older women with rheumatoid arthritis v. healthy controls. Public Health Nutrition 13(8): 1170-1177, 2010

The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health and Quality of Life Outcomes 7: 25, 2009

Therapeutic potential of IL-33 in rheumatoid arthritis: a comment about the article by Talabot-Ayer D, et al., "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis", Joint Bone Spine 2012;79:32-7. Joint Bone Spine 80(1): 116-117, 2013

Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62(17): 2493-2537, 2002

IL-17 levels in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: Target validation in various forms of arthritis. Annals of the Rheumatic Diseases 70(Suppl 2): A79-A79, 2011

Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Best Practice and Research. Clinical Rheumatology 18(6): 847-860, 2004

Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database of Systematic Reviews 2011(10): Cd008886, 2011

AB1073Prevalence of Comorbidities in Early Stages of Inflammatory Arthritis: A Comparison of Two Cohorts of Patients with Rheumatoid Arthritis and Psoriatic Arthritis:. Annals of the Rheumatic Diseases 73(Suppl 2): 1156.1-1156, 2014

Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Database of Systematic Reviews 1: Cd008951, 2012

Characterization of cells expressing citrullinated proteins in synovial tissue of patients with rheumatoid arthritis (RA), reactive arthritis (REA), psoriatic arthritis (PSA) and osteoarthritis (OA). 2007

Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors. Clinical and Experimental Rheumatology 33(6): 795-804, 2016